Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors

References

• Marai I., Zandman‐Goddard G., Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004; 33: 365–72
   PubMed Web of Science ®Google Scholar
• Arnout J., Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931–42
   PubMed Web of Science ®Google Scholar
• Rand J. H. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29–37
   PubMed Web of Science ®Google Scholar
• Pierangeli S. S., Harris E. N. Probing antiphospholipid‐mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003; 12: 539–45
   PubMed Web of Science ®Google Scholar
• Esmon C. T. The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321–7
   PubMed Web of Science ®Google Scholar
• Giesen P. L. A., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J. T., et al. Blood‐borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311–15
   PubMed Web of Science ®Google Scholar
• Mok C. C. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 85–95
   PubMed Web of Science ®Google Scholar
• Anderson F. A Jr., Spencer F. A. Risk factors for venous thromboembolism. Circulation 2003; 107: I–9–16
   Google Scholar
• Brouwer J. L. P., Bijl M., Veeger N. J. G. M., Kluin‐Nelemans H. C., van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143–8
   PubMed Web of Science ®Google Scholar
• Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7
   PubMed Web of Science ®Google Scholar
• Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R. M. A common genetic variation in the 3′‐untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703
   PubMed Web of Science ®Google Scholar
• Balogh I., Poka R., Pfliegler G., Dekany M., Boda Z., Muszbek L. High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost 1999; 81: 660–1
   PubMedGoogle Scholar
• Pongracz E., Tordai A., Csornai M., Bela Z., Nagy Z. Significance of Factor V gene A506G mutation (Leiden) in the pathogenesis of ischemic stroke. Ideggyogy Sz 2003; 56: 157–64
   PubMedGoogle Scholar
• Stankovics J., Melegh B., Nagy A., Kis A., Molnar J., Losonczy H., et al. Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population. Orv Hetil 1998; 139: 1161–3
   PubMedGoogle Scholar
• Griffin J. H., Evatt B., Zimmerman T. S., Kleiss A. J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370–3
   PubMed Web of Science ®Google Scholar
• Schwartz H. P., Fischer M., Hopmeier P., Batard M. A., Griffin J. H. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297–300
   PubMedGoogle Scholar
• Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516–30
   PubMedGoogle Scholar
• Tran M., Pharm D., Spencer F. A. Thromboepidemiology: identifying patients with heritable risk for thrombin‐mediated thromboembolic events. Am Heart J 2005; 149: S9–18
   Google Scholar
• Bucciarelli P., Rosendaal F. R., Tripodi A., Mannucci P. M., De Stefano V., Palareti G., et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19: 1026–33
   PubMed Web of Science ®Google Scholar
• Bertina R. M. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003/2004; 33: 399–400
   Google Scholar
• Kyrle P. A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457–62
   PubMed Web of Science ®Google Scholar
• Koster T., Blann A. D., Briet E., Vandenbroucke J. P., Rosendaal F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep‐vein thrombosis. Lancet 1995; 345: 152–5
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165–76
   PubMed Web of Science ®Google Scholar
• Afeltra A., Vadacca M., Conti L., Galluzzo S., Mitterhofer A. P., Ferri G. M., et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum 2005; 53: 452–9
   PubMedGoogle Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–40
   PubMed Web of Science ®Google Scholar
• Male C., Mitchell L., Julian J., Vegh P., Joshua P., Adams M., et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 844–9
   PubMed Web of Science ®Google Scholar
• Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., et al. The European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10‐year period. Medicine 2003; 82: 299–308
   PubMed Web of Science ®Google Scholar
• Mok C. C., Tang S. S., To C. H., Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774–82
   PubMed Web of Science ®Google Scholar
• Nordstrom M., Lindblad B., Bergqvist D., Kjellstrom T. A prospective study of the incidence of deep‐vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155–60
   PubMed Web of Science ®Google Scholar
• Anderson F. A Jr., Wheeler H. B., Goldberg R. J., Hosmer D. W., Patwardhan N. A., Jovanovic B., et al. A population‐based perspective of the hospital incidence and case‐fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933–8
   PubMed Web of Science ®Google Scholar
• Erkan D., Yazici Y., Peterson M. G., Sammaritano L., Lockshin M. D. A cross‐sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924–9
   PubMed Web of Science ®Google Scholar
• Shapiro S. S. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996; 47: 533–53
   PubMed Web of Science ®Google Scholar
• Galli M., Barbui T. Prevalence of different anti‐phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001; 47: 985–7
   PubMedGoogle Scholar
• Love P. E., Santoro S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non‐SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682–98
   PubMed Web of Science ®Google Scholar
• Palomo I., Pereira J., Alarcon M., Larrain A. M., Pinochet C., Vasquez M., et al. Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. J Lab Clin Med 2002; 140: 336–41
   PubMedGoogle Scholar
• Radway‐Bright E. L., Ravirajan C. T., Isenberg D. A. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology (Oxford) 2000; 39: 427–31
   PubMedGoogle Scholar
• Caccavo D., Del Porto F., Garzia P., Mitterhofer A. P., Galluzzo S., Rigon A., et al. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?. Ann Rheum Dis 2003; 62: 1003–5
   PubMedGoogle Scholar
• Sebastiani G. D., Galeazzi M., Tincani A., Piette J. C., Font J., Allegri F., et al. Anticardiolipin and anti‐beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28: 344–51
   PubMedGoogle Scholar
• Gould T., Tikly M., Asherson R., Loizou S., Singh S. Prevalence and clinical correlates of anti‐phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29–34
   PubMed Web of Science ®Google Scholar
• Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4
   PubMed Web of Science ®Google Scholar
• Lucotte G., Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001; 27: 362–7
   PubMedGoogle Scholar
• Koster T., Blann A. D., Briet E., Vandenbroucke J. P., Rosendaal F. R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep‐vein thrombosis. Lancet 1995; 345: 152–5
   PubMed Web of Science ®Google Scholar
• Simioni P., Prandoni P., Burlina A., Tormene D., Sardella C., Ferrari V., et al. Hyperhomocysteinemia and deep‐vein thrombosis. A case–control study. Thromb Haemost 1996; 76: 883–6
   PubMedGoogle Scholar
• Levine S. R., Kieran S., Puzio K., Feit H., Patel S. C., Welch K. M. Cerebral venous thrombosis with lupus anticoagulants. Report of two cases. Stroke 1987; 18: 801–4
   PubMedGoogle Scholar
• Levy D. M., Massicotte M. P., Harvey E., Hebert D., Silverman E. D. Thromboembolism in paediatric lupus patients. Lupus 2003; 12: 741–6
   PubMed Web of Science ®Google Scholar
• Calvo‐Alén J., Toloza S. M., Fernández M., Bastian H. M., Fessler B. J., Roseman J. M., et al. The LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060–8
   PubMed Web of Science ®Google Scholar